The Three A’s of Launch Readiness – Strategizing for success

Jesper Nissen

It can take years to develop a drug – a launch can fail in a matter of weeks

Getting a drug from bench to launch takes an average of 12 years and $1.5 billion.1 Given responsible guardianship and the careful promotion to be expected at that level of investment, it should come as a surprise when any drug falls flat at launch.

But it doesn’t – drug launch failures happen more frequently than pharma companies care to admit. From 2009-2017, approximately 50% of drug launches failed to meet prelaunch sales expectations. Over 25% didn’t meet half their forecasted revenues.2 Of the 0.02% of candidate drugs (I in 5000) that successfully reach the market, only a third meet first-year financial expectation.3

And when launches fail, the rationalizations begin: Bad luck. Bad timetables. Unforeseen complications. Unforeseeable competition. The messaging underwhelmed the target audiences. The drug costs overwhelmed the messaging. The drug overpromised, the drug underperformed.

Any and all of these may be true. But, when each case is scrutinized individually, the evidence usually points to one of three problems: the pharma brand managers and their teams did not anticipate their own overconfidence or the moves of their competitors, they did not adapt their strategies to new market conditions as they arose, or they did not align their strategy and implementation plans across functions and geographies.

Anticipate, Adapt and Align – the three A’s of successful launch strategy. To understand and implement them require more than sending out an email meeting request and marking off a block of squares on a Gantt chart. It takes strategic vision, a holistic understanding of every vagary of the marketplace, and a forthright and ruthlessly honest assessment of both the product being launched and the competitive space it is meant to occupy.

Deallus Three As of Launch Readiness White paper
DOWNLOAD WHITE PAPER

About the author

Jesper Nissen Deallus Principal, London

Jesper Nissen, PhD

Jesper is a Deallus Senior Principal who has led a wide range of projects over his 6+ years at Deallus. He offers extensive experience in competitive landscape monitoring, manufacturing and diagnostics technology assessments, and global positioning and brand planning projects. His expertise covers several therapy areas including oncology, respiratory, rheumatology and rare diseases. Additionally, Jesper is leading internal and external training activities including engagements on competitive readiness best practices within the pharmaceutical industry.

You may also be interested in…

  • AI in pharma

Can AI really help you understand what matters in your market?

The impact of AI across our industry will be profound. It’s already driving faster identification of novel drug targets and drug discovery, better patient identification, accelerated drug development, earlier diagnosis, and more personalized healthcare.

  • Brain Awareness Week

Brain Awareness Week

Brain Awareness Week is a global campaign held every March that aims to increase public support and excitement for brain science.

  • Rare Disease Day

Rare Diseases, Pharma’s Perennial Hitmaker

February 29th is the rarest day of the year, and this was in fact the reason why Rare Disease Day was established on this day 16 years ago by the European Organisation for Rare Diseases, commemorating the 25th anniversary of the U.S. Orphan Drug Act.

  • National Healthcare Security Administration (NHSA) protocols

National Healthcare Security Administration (NHSA) protocols

On 4 July 2023, the National Healthcare Security Administration (NHSA) published the drafted 'Protocol for Renewal of NRDL Listed Drugs’ and ‘Negotiation Rules for Non-Exclusive Drug’. The two protocols aim to streamline the negotiation process for NRDL listed drugs and those with generic versions and are eligible for NRDL listing.